Summary of Study ST002484
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001606. The data can be accessed directly via it's Project DOI: 10.21228/M83T4M This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST002484 |
Study Title | Metabolomic analysis of maternal mid-gestation plasma and cord blood: primary metabolism |
Study Summary | Metabolomic analysis of maternal mid-gestation plasma and cord blood reveals evidence in autism spectrum disorder of inflammation, disruption of membrane integrity, and impaired neurotransmission and neurotoxicity. The discovery of prenatal and neonatal molecular biomarkers has the potential to yield insights into autism spectrum disorder (ASD) and facilitate early diagnosis. We characterized metabolomic profiles in ASD using plasma samples collected in the Norwegian Autism Birth Cohort from mothers at weeks 17-21 gestation (maternal mid-gestation, MMG, n=408) and from children on the day of birth (cord blood, CB, n=418). We analyzed associations using sex-stratified adjusted logistic regression models with Bayesian analyses. Chemical enrichment analyses (ChemRICH) were performed to determine altered chemical clusters. We also employed machine learning algorithms to assess the utility of metabolomics as ASD biomarkers. We identified ASD associations with a variety of chemical compounds including arachidonic acid, glutamate, and glutamine, and metabolite clusters including hydroxy eicospentaenoic acids, phosphatidylcholines, and ceramides in MMG and CB plasma that are consistent with inflammation, disruption of membrane integrity, and impaired neurotransmission and neurotoxicity. Girls with ASD have disruption of ether/non-ether phospholipid balance in the MMG plasma that is similar to that found in other neurodevelopmental disorders. ASD boys in the CB analyses had the highest number of dysregulated chemical clusters. Machine learning classifiers distinguished ASD cases from controls with AUC values ranging from 0.710 to 0.853. Predictive performance was better in CB analyses than in MMG. These findings may provide new insights into the sex-specific differences in ASD and have implications for discovery of biomarkers that may enable early diagnosis and intervention. |
Institute | Columbia University |
Last Name | Lipkin |
First Name | W. Ian |
Address | 722 W. 168th St., 17th Floor, New York, NY, 10032 |
wil2001@cumc.columbia.edu | |
Phone | (212) 342-9033 |
Submit Date | 2023-02-21 |
Raw Data Available | Yes |
Raw Data File Type(s) | cdf |
Analysis Type Detail | GC-MS |
Release Date | 2023-07-02 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR001606 |
Project DOI: | doi: 10.21228/M83T4M |
Project Title: | Metabolomic analysis of maternal mid-gestation plasma and cord blood |
Project Summary: | Metabolomic analysis of maternal mid-gestation plasma and cord blood reveals evidence in autism spectrum disorder of inflammation, disruption of membrane integrity, and impaired neurotransmission and neurotoxicity. The discovery of prenatal and neonatal molecular biomarkers has the potential to yield insights into autism spectrum disorder (ASD) and facilitate early diagnosis. We characterized metabolomic profiles in ASD using plasma samples collected in the Norwegian Autism Birth Cohort from mothers at weeks 17-21 gestation (maternal mid-gestation, MMG, n=408) and from children on the day of birth (cord blood, CB, n=418). We analyzed associations using sex-stratified adjusted logistic regression models with Bayesian analyses. Chemical enrichment analyses (ChemRICH) were performed to determine altered chemical clusters. We also employed machine learning algorithms to assess the utility of metabolomics as ASD biomarkers. We identified ASD associations with a variety of chemical compounds including arachidonic acid, glutamate, and glutamine, and metabolite clusters including hydroxy eicospentaenoic acids, phosphatidylcholines, and ceramides in MMG and CB plasma that are consistent with inflammation, disruption of membrane integrity, and impaired neurotransmission and neurotoxicity. Girls with ASD have disruption of ether/non-ether phospholipid balance in the MMG plasma that is similar to that found in other neurodevelopmental disorders. ASD boys in the CB analyses had the highest number of dysregulated chemical clusters. Machine learning classifiers distinguished ASD cases from controls with AUC values ranging from 0.710 to 0.853. Predictive performance was better in CB analyses than in MMG. These findings may provide new insights into the sex-specific differences in ASD and have implications for discovery of biomarkers that may enable early diagnosis and intervention. |
Institute: | Columbia University |
Department: | Center for Infection and Immunity |
Laboratory: | Center for Infection and Immunity |
Last Name: | Lipkin |
First Name: | W. Ian |
Address: | 722 W. 168th St., 17th Floor, New York, NY, 10032 |
Email: | wil2001@cumc.columbia.edu |
Phone: | (212) 342-9033 |
Subject:
Subject ID: | SU002804 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Factors:
Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)
mb_sample_id | local_sample_id | Sex | Diagnosis |
---|---|---|---|
SA269536 | ABC-17438_315 | Female | CASE |
SA269537 | ABC-19850_538 | Female | CASE |
SA269538 | ABC-17316_307 | Female | CASE |
SA269539 | ABC-17926_418 | Female | CASE |
SA269540 | ABC-19930_264 | Female | CASE |
SA269541 | ABC-19926_722 | Female | CASE |
SA269542 | ABC-19756_272 | Female | CASE |
SA269543 | ABC-19881_776 | Female | CASE |
SA269544 | ABC-19714_984 | Female | CASE |
SA269545 | ABC-10358_478 | Female | CASE |
SA269546 | ABC-9987_885 | Female | CASE |
SA269547 | ABC-19205_624 | Female | CASE |
SA269548 | ABC-19210_658 | Female | CASE |
SA269549 | ABC-18865_686 | Female | CASE |
SA269550 | ABC-19283_383 | Female | CASE |
SA269551 | ABC-17760_948 | Female | CASE |
SA269552 | ABC-19202_238 | Female | CASE |
SA269553 | ABC-19047_503 | Female | CASE |
SA269554 | ABC-17759_615 | Female | CASE |
SA269555 | ABC-19050_632 | Female | CASE |
SA269556 | ABC-17697_966 | Female | CASE |
SA269557 | ABC-17671_849 | Female | CASE |
SA269558 | ABC-10032_831 | Female | CASE |
SA269559 | ABC-18778_694 | Female | CASE |
SA269560 | ABC-18738_564 | Female | CASE |
SA269561 | ABC-18908_221 | Female | CASE |
SA269562 | ABC-17540_605 | Female | CASE |
SA269563 | ABC-19574_256 | Female | CASE |
SA269564 | ABC-19632_857 | Female | CASE |
SA269565 | ABC-19465_469 | Female | CASE |
SA269566 | ABC-19458_712 | Female | CASE |
SA269567 | ABC-19407_785 | Female | CASE |
SA269568 | ABC-18756_323 | Female | CASE |
SA269569 | ABC-7113_358 | Female | CASE |
SA269570 | ABC-19438_730 | Female | CASE |
SA269571 | ABC-17482_374 | Female | CASE |
SA269572 | ABC-16983_1018 | Female | CASE |
SA269573 | ABC-16466_246 | Female | CASE |
SA269574 | ABC-21723_921 | Female | CASE |
SA269575 | ABC-4191_443 | Female | CASE |
SA269576 | ABC-16430_821 | Female | CASE |
SA269577 | ABC-21823_513 | Female | CASE |
SA269578 | ABC-2180_487 | Female | CASE |
SA269579 | ABC-4344_332 | Female | CASE |
SA269580 | ABC-16602_893 | Female | CASE |
SA269581 | ABC-21479_903 | Female | CASE |
SA269582 | ABC-21476_348 | Female | CASE |
SA269583 | ABC-20046_451 | Female | CASE |
SA269584 | ABC-21537_554 | Female | CASE |
SA269585 | ABC-21684_495 | Female | CASE |
SA269586 | ABC-16673_929 | Female | CASE |
SA269587 | ABC-11191_867 | Female | CASE |
SA269588 | ABC-16329_521 | Female | CASE |
SA269589 | ABC-2332_813 | Female | CASE |
SA269590 | ABC-3185_230 | Female | CASE |
SA269591 | ABC-3138_409 | Female | CASE |
SA269592 | ABC-11725_580 | Female | CASE |
SA269593 | ABC-2881_650 | Female | CASE |
SA269594 | ABC-11634_461 | Female | CASE |
SA269595 | ABC-11918_1010 | Female | CASE |
SA269596 | ABC-2299_640 | Female | CASE |
SA269597 | ABC-21970_758 | Female | CASE |
SA269598 | ABC-3681_529 | Female | CASE |
SA269599 | ABC-2200_426 | Female | CASE |
SA269600 | ABC-2262_958 | Female | CASE |
SA269601 | ABC-2298_205 | Female | CASE |
SA269602 | ABC-3414_546 | Female | CASE |
SA269603 | ABC-16796_911 | Female | CASE |
SA269604 | ABC-21528_366 | Female | CASE |
SA269605 | ABC-20903_391 | Female | CASE |
SA269606 | ABC-20900_795 | Female | CASE |
SA269607 | ABC-5666_766 | Female | CASE |
SA269608 | ABC-21379_213 | Female | CASE |
SA269609 | ABC-20953_748 | Female | CASE |
SA269610 | ABC-20952_572 | Female | CASE |
SA269611 | ABC-20870_589 | Female | CASE |
SA269612 | ABC-20867_994 | Female | CASE |
SA269613 | ABC-20769_597 | Female | CASE |
SA269614 | ABC-20531_289 | Female | CASE |
SA269615 | ABC-20792_1002 | Female | CASE |
SA269616 | ABC-17221_668 | Female | CASE |
SA269617 | ABC-20853_803 | Female | CASE |
SA269618 | ABC-5893_875 | Female | CASE |
SA269619 | ABC-20956_340 | Female | CASE |
SA269620 | ABC-20950_976 | Female | CASE |
SA269621 | ABC-21073_839 | Female | CASE |
SA269622 | ABC-16993_740 | Female | CASE |
SA269623 | ABC-21076_435 | Female | CASE |
SA269624 | ABC-16904_676 | Female | CASE |
SA269625 | ABC-21318_399 | Female | CASE |
SA269626 | ABC-16997_281 | Female | CASE |
SA269627 | ABC-2836_939 | Female | CASE |
SA269628 | ABC-21004_704 | Female | CASE |
SA269629 | ABC-21007_297 | Female | CASE |
SA269630 | ABC-8388_840 | Female | CONTROL |
SA269631 | ABC-8876_1003 | Female | CONTROL |
SA269632 | ABC-9061_651 | Female | CONTROL |
SA269633 | ABC-8355_452 | Female | CONTROL |
SA269634 | ABC-8614_539 | Female | CONTROL |
SA269635 | ABC-9565_341 | Female | CONTROL |
Collection:
Collection ID: | CO002797 |
Collection Summary: | Spun inside centrifuge and processed |
Sample Type: | Blood (plasma) |
Treatment:
Treatment ID: | TR002813 |
Treatment Summary: | NA |
Sample Preparation:
Sampleprep ID: | SP002810 |
Sampleprep Summary: | SOP blood-LCGCextract-02252019 |
Sampleprep Protocol Filename: | SOP_blood-LCGCextract-02252019.docx |
Combined analysis:
Analysis ID | AN004375 |
---|---|
Analysis type | MS |
Chromatography type | GC |
Chromatography system | Agilent 7890 GC- Pegasus IV TOF MS |
Column | Restek Rtx-5Sil MS (30m x 0.25mm, 0.25um) |
MS Type | EI |
MS instrument type | GC-TOF |
MS instrument name | Leco Pegasus IV TOF |
Ion Mode | POSITIVE |
Units | normalized peak heights |
Chromatography:
Chromatography ID: | CH003281 |
Instrument Name: | Agilent 7890 GC- Pegasus IV TOF MS |
Column Name: | Restek Rtx-5Sil MS (30m x 0.25mm, 0.25um) |
Column Temperature: | NA |
Flow Gradient: | NA |
Flow Rate: | 1 mL/min |
Solvent A: | NA |
Solvent B: | NA |
Chromatography Type: | GC |
MS:
MS ID: | MS004124 |
Analysis ID: | AN004375 |
Instrument Name: | Leco Pegasus IV TOF |
Instrument Type: | GC-TOF |
MS Type: | EI |
MS Comments: | Mass spectrometer settings: A Leco Pegasus IV time of flight mass spectrometer is controlled by the Leco ChromaTOF software vs. 2.32 (St. Joseph, MI). The transfer line temperature between gas chromatograph and mass spectrometer is set to 280°C. Electron impact ionization at 70V is employed with an ion source temperature of 250°C. Acquisition rate is 17 spectra/second, with a scan mass range of 85-500 Da. |
Ion Mode: | POSITIVE |